96 related articles for article (PubMed ID: 26096009)
1. Targeted sequencing of cancer-associated genes in hepatocellular carcinoma using next generation sequencing.
Lu J; Yin J; Dong R; Yang T; Yuan L; Zang L; Xu C; Peng B; Zhao J; Du X
Mol Med Rep; 2015 Sep; 12(3):4678-4682. PubMed ID: 26096009
[TBL] [Abstract][Full Text] [Related]
2. Next generation sequencing reveals genetic landscape of hepatocellular carcinomas.
Li S; Mao M
Cancer Lett; 2013 Nov; 340(2):247-53. PubMed ID: 23063663
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.
Labgaa I; Villacorta-Martin C; D'Avola D; Craig AJ; von Felden J; Martins-Filho SN; Sia D; Stueck A; Ward SC; Fiel MI; Mahajan M; Tabrizian P; Thung SN; Ang C; Friedman SL; Llovet JM; Schwartz M; Villanueva A
Oncogene; 2018 Jul; 37(27):3740-3752. PubMed ID: 29628508
[TBL] [Abstract][Full Text] [Related]
4. Inhibition mechanism of a newly cloned candidate tumor suppressor gene JST during hepatocarcinogenesis and its abnormal expression in human hepatocellular carcinoma from Qidong liver cancer risk area, China.
Dong-Dong L; Xi-Ran Z
Hepatogastroenterology; 2004; 51(56):515-25. PubMed ID: 15086194
[TBL] [Abstract][Full Text] [Related]
5. Correlation of TP53 mutations with HCV positivity in hepatocarcinogenesis: identification of a novel TP53 microindel in hepatocellular carcinoma with HCV infection.
Long J; Wang Y; Li M; Tong WM; Jia JD; Huang J
Oncol Rep; 2013 Jul; 30(1):119-24. PubMed ID: 23624687
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
[TBL] [Abstract][Full Text] [Related]
7. The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure.
Qi LN; Bai T; Chen ZS; Wu FX; Chen YY; De Xiang B; Peng T; Han ZG; Li LQ
Liver Int; 2015 Mar; 35(3):999-1009. PubMed ID: 24461059
[TBL] [Abstract][Full Text] [Related]
8. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
[TBL] [Abstract][Full Text] [Related]
9. Correlation between clinical characteristics and mitochondrial D-loop DNA mutations in hepatocellular carcinoma.
Tamori A; Nishiguchi S; Nishikawa M; Kubo S; Koh N; Hirohashi K; Shiomi S; Inoue M
J Gastroenterol; 2004 Nov; 39(11):1063-8. PubMed ID: 15580399
[TBL] [Abstract][Full Text] [Related]
10. Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan.
Shirabe K; Toshima T; Taketomi A; Taguchi K; Yoshizumi T; Uchiyama H; Harimoto N; Kajiyama K; Egashira A; Maehara Y
Liver Int; 2011 Oct; 31(9):1366-72. PubMed ID: 21745313
[TBL] [Abstract][Full Text] [Related]
11. Whole genome sequencing of matched tumor, adjacent non-tumor tissues and corresponding normal blood samples of hepatocellular carcinoma patients revealed dynamic changes of the mutations profiles during hepatocarcinogenesis.
Mao R; Liu J; Liu G; Jin S; Xue Q; Ma L; Fu Y; Zhao N; Xing J; Li L; Qiu Y; Lin B
Oncotarget; 2017 Apr; 8(16):26185-26199. PubMed ID: 28412734
[TBL] [Abstract][Full Text] [Related]
12. SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma.
Zhang ZY; Hong D; Nam SH; Kim JM; Paik YH; Joh JW; Kwon CH; Park JB; Choi GS; Jang KY; Park CK; Kim SJ
J Hepatol; 2015 Jan; 62(1):121-30. PubMed ID: 25131770
[TBL] [Abstract][Full Text] [Related]
13. Mutational hotspot in the p53 gene in human hepatocellular carcinomas.
Hsu IC; Metcalf RA; Sun T; Welsh JA; Wang NJ; Harris CC
Nature; 1991 Apr; 350(6317):427-8. PubMed ID: 1849234
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
[TBL] [Abstract][Full Text] [Related]
15. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
Hussain SP; Schwank J; Staib F; Wang XW; Harris CC
Oncogene; 2007 Apr; 26(15):2166-76. PubMed ID: 17401425
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.
Kelley RK; Magbanua MJ; Butler TM; Collisson EA; Hwang J; Sidiropoulos N; Evason K; McWhirter RM; Hameed B; Wayne EM; Yao FY; Venook AP; Park JW
BMC Cancer; 2015 Mar; 15():206. PubMed ID: 25884197
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations in hepatocellular carcinoma: An update.
Niu ZS; Niu XJ; Wang WH
World J Gastroenterol; 2016 Nov; 22(41):9069-9095. PubMed ID: 27895396
[TBL] [Abstract][Full Text] [Related]
18. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.
Bressac B; Kew M; Wands J; Ozturk M
Nature; 1991 Apr; 350(6317):429-31. PubMed ID: 1672732
[TBL] [Abstract][Full Text] [Related]
19. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
[TBL] [Abstract][Full Text] [Related]
20. Association of a potential functional pre-miR-218 polymorphism and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk.
Han Y; Pu R; Han X; Zhao J; Li W; Yin J; Zhang Y; Shen Q; Xie J; Zhang Q; Jiang S; Li J; Zhang H; Wang H; Cao G
Liver Int; 2014 May; 34(5):728-36. PubMed ID: 24118778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]